Preliminary results with the new cytostatic Penberol in ovarian carcinoma.
The authors present results of a preliminary study on the efficiency of the preparation Penberol [VUFB Prague (cis-beta-4-pentoxy-benzoyl-beta-bromoacrylic acid) CHECO protocol number 4] in the ovarian carcinoma of the stage III and IV (FIGO) in which the drug was used after the failure of the first choice chemotherapy. Out of ten patients, complete regression of the lesions was achieved in 7 patients, only in two cases the regression was lower than 50% and in one case a progression was encountered during the therapy. The median of the duration of non-completed remission is 15+ months. As to the side effects, in half cases the dose of the preparation was reduced by 1/3 because of diarrhea induced by irritating action of the drug on the intestinal wall. No other side effects of the therapy were observed.
D000179:Acrylates / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D013997:Time Factors
D000179:Acrylates; D000970:Antineoplastic Agents; C012473:Penberol